ADTX - צמיחת מכירות משנה לשנה (TTM) Aditxt

Aditxt specializes in immune reprogramming, utilizing the Pears platform for precise graft control. Meanwhile, management is adapting to high volatility and active mergers, which is eroding shareholder confidence. The LTM annual sales growth rate demonstrates business dynamics where the -74.20 level represents the current value. Its first-mover status in personalized medicine strengthens the brand's reputation.

This indicator filters out market noise by measuring the percentage growth rate of the rolling annual revenue to distinguish random spikes from a sustainable trend. The current value of -74.20 in comparable year-over-year sales growth over 12 months reflects the financial efficiency of scaling Aditxt (ADTX) autonomous AI platforms, AditxtScore, and robotic dispensers in clinical laboratories, confirming the actual commercialization of the company's technologies.